Acadia Realty Trust
$4.61B- Market cap
- $2.79B
- Debt
- +$1.86B
- Cash
- −$38.82M
Capital structure 60% equity / 40% debt · EV / Revenue 11.22x · EV / EBITDA 34.32x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AKR stock price vs VNDA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VNDA's multiple
Needs VNDA P/E.
Implied fair value · at AKR's multiple
Needs EPS (TTM) is negative, AKR P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AKR FY 2025 (ended Dec 31, 2025) · VNDA FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 60% equity / 40% debt · EV / Revenue 11.22x · EV / EBITDA 34.32x
Capital structure 81% equity / 19% debt · EV / Revenue 1.49x
AKR carries the larger enterprise value at $4.61B against $321.69M; VNDA trades on the lower EV / Revenue multiple (1.49x vs 11.22x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ACADIA REALTY TRUST · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
VANDA PHARMACEUTICALS INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.84x
0.24x
Net debt / EBITDA
Leverage against operating earnings
13.58x
0.05x
Cash and equivalents
Liquid reserves on the balance sheet
$38.82M
$84.85M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AVALONBAY COMMUNITIES INC
AKR vs AVB
UDR, Inc.
AKR vs UDR
REALTY INCOME CORP
AKR vs O
SUPERNUS PHARMACEUTICALS, INC.
AKR vs SUPN
CATALYST PHARMACEUTICALS, INC.
AKR vs CPRX
Harmony Biosciences Holdings, Inc.
AKR vs HRMY
ELI LILLY & Co
AKR vs LLY
INCYTE CORP
AKR vs INCY
Sarepta Therapeutics, Inc.
AKR vs SRPT
$1.86B
$78.23M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.